Nephros reports preliminary Q2 2021 revenue $2.2M (+40% YoY); submits HDF product for FDA 510(k) clearance

NEPHROS INC

Preliminary Q2 2021 net revenue ~$2.2M, >40% year-over-year increase.
Six-month revenue >$5M, up 20% vs same periods in 2020 and 2019.
Subsidiary SRP submitted HDF Assist Module for FDA 510(k) clearance; commercial launch planned at limited dialysis clinics.
Pathogen Detection Systems segment generated >$50k in Q2 from on-site testing services.
Consolidated cash at quarter end ~$8.3M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.